ArticleActa pharmaceutica Sinica. B2022

Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer.

Sha-Sha Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.